Categories: Technology

IDEX Biometrics ASA: Mandatory notification of trade – 11 June 2025

Kristian Flaten, CFO in IDEX Biometrics ASA, has bought 1,608,809 shares in IDEX Biometrics ASA, at a price of NOK 0.01 per share through the subsequent offering.

After this transaction, Flaten owns 2,608,809 shares in IDEX Biometrics ASA.

Please refer to the attached notification for further details.

For further information contact:

Kristian Flaten, CFO, Tel: +47 95092322

E-mail: ir@idexbiometrics.com

This information is subject to the disclosure requirements pursuant to Article 19 of the EU Market Abuse Regulation and Section 5-12 of the Norwegian Securities Trading Act.

GlobeNews Wire

Recent Posts

AvironiX Unveils AviSpray-10c, a Backpack-Sized Agricultural Spraying Drone for India’s Precision Farming Sector

CHENNAI, India, Dec. 8, 2025 /PRNewswire/ -- AvironiX Drones, a Chennai-based deep-tech drone company focused on precision farming and defence technologies, today…

2 hours ago

Abstract and Open World Partner to Launch the First National-Scale Tokenization Engine for the World’s Most Valuable Real-World Assets

For the first time, the world's most strategic assets—AI supercomputing centers, strategic real estate and…

2 hours ago

Navitas, Cyient Semiconductors enter into a strategic partnership to accelerate GaN adoption in India’s AI, Mobility, Industrial, and Energy Markets

TORRANCE, Calif. and HYDERABAD, India, Dec. 8, 2025 /PRNewswire/ -- Navitas Semiconductor Corporation (Nasdaq: NVTS),…

2 hours ago

DXC Appoints Russell Jukes as Chief Digital Information Officer to Strengthen Unified Digital Strategy

ASHBURN, Va., Dec. 8, 2025 /PRNewswire/ -- DXC Technology (NYSE: DXC), a leading enterprise technology and…

2 hours ago

Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI

Latest release enables faster, more confident design decisions at scale with accelerated simulation, AI-powered, real-time…

2 hours ago

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin…

2 hours ago